Credit Suisse’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Credit Suisse’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,600	Closed	-$264K	–	4268
2019 Q1	$264K	Buy	+3,600	New	+$245K	﹤0.01%	3655

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Credit Suisse's MRTX Position: Q1 2024 in Review

Credit Suisse sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 59,533 shares — an estimated $3.5M sold.

Credit Suisse first reported a position in MRTX in Q1 2014 and held it in 32 quarters. The position peaked at $70.2M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Credit Suisse reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Credit Suisse sold 59,533 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.5M.
Credit Suisse first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 32 quarters.
Credit Suisse's Mirati Therapeutics, Inc. Common Stock position peaked at $70.2M in Q3 2021.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.